{
    "nctId": "NCT00279448",
    "briefTitle": "Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer",
    "officialTitle": "Multicenter, Randomized, Open-Label Study To Compare The Efficacy, Tolerance And Quality Of Life Of 5 Years Of Adjuvant Exemestane (Aromasin) Therapy With 2.5 To 3 Years Of Adjuvant Tamoxifen Therapy, Followed By 2 To 2.5 Years Of Exemestane For A Total Duration Of 5 Years To Treat HR+ Post-Menopausal Patients With Non-Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 9779,
    "primaryOutcomeMeasure": "To compare recurrence free survival between two treatment groups.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* HR+ post-menopausal patients with non-metastatic breast cancer\n\nExclusion Criteria:\n\n* Any of the following: HR-, non-menopausal patient, metastatic breast cancer",
    "sex": "FEMALE",
    "minimumAge": "50 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}